MedTrace Logo

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

NCT01219543 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2013-01-08

No results posted yet for this study

Summary

This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer in the expansion phase and to evaluate daily and BID dosing.

Conditions

  • Solid Tumour
  • Advanced Solid Malignancies
  • Child-Pugh A to B7 Advanced Hepatocellular Carcinoma
  • EGFR and/or ROS Mutant NSCLC
  • Lung Metastasis Carcinoma
  • Gastric Cancer

Interventions

DRUG

AZD1480 Daily

Oral Dose, Capsule, Daily Dosing

DRUG

AZD1480 BID

Oral Dose, Capsule, BID Dosing

Sponsors & Collaborators

Principal Investigators

  • Becker Hewes, MD · AstraZeneca

  • Kang Yoon-Koo, MD, PhD · Asian Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219543 on ClinicalTrials.gov